查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1390889

速效胰島素市場：2023-2028 年全球產業趨勢、佔有率、規模、成長、機會與預測

Rapid Acting Insulin Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028
出版日期: | 出版商: IMARC | 英文 141 Pages | 商品交期: 2-3個工作天內

價格

概要

2022年全球速效胰島素市場規模達74億美元。展望未來， IMARC Group預計到2028年市場規模將達到97億美元，2022-2028年複合年成長率（CAGR）為4.61%。患者的嚴重程度和死亡風險不斷增加、大眾對個人化醫療的日益關注以及研發（R＆D）活動投資的增加是推動市場的一些主要因素。

速效胰島素是一種用於治療糖尿病的胰島素，特別是用於控制餐後血糖高峰。它旨在模仿人體進食後的自然胰島素反應，注射後 15 分鐘內起效。這種迅速的作用有助於有效控制血糖水平，因為它可以調節人體的葡萄糖代謝。速效胰島素在給藥後一到兩個小時左右發揮作用高峰，使其能夠在這段關鍵時期有效降低高血糖水平。它允許糖尿病患者根據膳食消耗來安排注射時間，從而提供更個人化的治療方法。它增強了糖尿病管理，為患者提供更好的生活品質，並降低與血糖水平失控相關的併發症風險。

速效胰島素是一種用於治療糖尿病的胰島素，特別是用於控制餐後血糖高峰。它旨在模仿人體進食後的自然胰島素反應，注射後 15 分鐘內起效。這種迅速的作用有助於有效控制血糖水平，因為它可以調節人體的葡萄糖代謝。速效胰島素在給藥後一到兩個小時左右發揮作用高峰，使其能夠在這段關鍵時期有效降低高血糖水平。它允許糖尿病患者根據膳食消耗來安排注射時間，從而提供更個人化的治療方法。它增強了糖尿病管理，為患者提供更好的生活品質，並降低與血糖水平失控相關的併發症風險。

速效胰島素市場趨勢/促進因素：

大眾中糖尿病盛行率不斷上升

全世界糖尿病的發生率正以驚人的速度上升。久坐的生活方式、不健康的飲食習慣和肥胖是導致糖尿病發病率上升的一些關鍵因素。隨著越來越多的人被診斷出患有糖尿病，對有效且速效胰島素的需求持續成長。速效胰島素在控制餐後血糖高峰方面發揮著至關重要的作用，為患者提供更快、更有效的控制血糖水平的方法。醫療保健提供者擴大開出速效胰島素來滿足餐後即時的胰島素需求，從而降低高血糖和相關併發症的風險。隨著糖尿病人口的增加，製藥公司正在加大研發投入，以改善速效胰島素配方，提高其功效並為患者提供便利。

持續的技術進步

醫療技術的創新徹底改變了胰島素輸送系統，使其更加方便用戶使用和準確。胰島素筆、胰島素幫浦和連續血糖監測 (CGM) 設備在糖尿病患者中越來越受歡迎，有助於更輕鬆地管理和精確劑量的胰島素。速效胰島素製劑旨在與這些現代輸送系統完美配合，進一步滿足他們的需求。胰島素筆提供謹慎、方便的胰島素輸送，而胰島素幫浦則根據個人需求提供連續、個人化的胰島素輸注。這些技術創新改善了血糖控制，降低了低血糖發作的風險，並提高了患者的整體生活品質。因此，速效胰島素與這些先進設備的兼容性已成為市場成長的重要動力。

提高意識和醫療基礎設施

人們對糖尿病及其管理的認知不斷提高，加上醫療基礎設施的擴大，大大增加了對速效胰島素的需求。糖尿病意識活動、教育措施和篩檢計畫促進了患者的早期診斷和及時干預，從而增加了尋求適當治療的人數。醫生和醫療保健專業人員擴大開出速效胰島素，以幫助患者更好地控制餐後血糖，並預防高血糖發作和長期併發症。此外，政府和醫療保健組織正在投資糖尿病管理計劃，改善獲得基本藥物的機會，包括速效胰島素。意識的提高、醫療設施的改善以及糖尿病治療負擔能力的提高，為速效胰島素市場的擴張創造了有利的環境。

速效胰島素產業細分：

IMARC Group提供了全球速效胰島素市場報告各細分市場主要趨勢的分析，以及 2023-2028 年全球、區域和國家層面的預測。我們的報告根據產品、適應症和配銷通路對市場進行了分類。

按產品分類：

賴脯胰島素

門冬胰島素

谷賴胰島素

賴脯胰島素主導市場

該報告根據產品提供了詳細的市場細分和分析。這包括賴脯胰島素、門冬胰島素和谷賴胰島素。根據該報告，賴脯胰島素代表了最大的細分市場。

賴脯胰島素的受歡迎可歸因於其快速起效，通常在給藥後幾分鐘內起效，這有助於更有效地控制餐後血糖高峰。這種快速的作用使糖尿病患者能夠將胰島素注射時間安排得更接近用餐時間，從而在管理血糖水平方面提供更大的靈活性和便利性。此外，賴脯胰島素與各種胰島素輸送設備相容，例如胰島素筆和胰島素泵，進一步提高了其易用性和患者依從性。除此之外，由於其經過驗證的功效和安全性，許多醫生和醫療保健提供者經常開出賴脯胰島素。它已證明其在治療 1 型和 2 型糖尿病方面的有效性，使其成為廣大患者的多功能選擇。

按指示細分：

1 型糖尿病

2型糖尿病

2型糖尿病佔最大市場佔有率

報告還提供了基於該指標的詳細市場細分和分析。這包括第 1 型糖尿病和第 2 型糖尿病。報告稱，第2型糖尿病佔了最大的市場佔有率。

2 型糖尿病是一種慢性代謝性疾病，其特徵是胰島素阻抗和葡萄糖調節受損，導致血糖水平升高。速效胰島素在第 2 型糖尿病的治療中發揮著至關重要的作用，特別是在解決餐後高血糖方面。飯後，人們的血糖水平通常會迅速升高，如果不加以控制，可能會導致各種健康併發症。隨著人們對糖尿病及其管理的認知不斷提高，再加上改善醫療保健和糖尿病護理機會的努力，對速效胰島素的需求預計將仍然巨大，從而鞏固其在市場上的突出地位。在久坐的生活方式、肥胖和人口老化等因素的推動下，2 型糖尿病的盛行率不斷上升，導致越來越多的患者尋求糖尿病管理解決方案。

按配銷通路分類：

醫院藥房

藥局和零售藥局

網路商店

藥局和零售藥局佔據市場最大佔有率

報告還根據配銷通路對市場進行了詳細的細分和分析。這包括醫院藥局、藥局、零售藥局和網路商店。報告顯示，藥局和零售藥局佔據了最大的市場佔有率。

藥局和零售藥局分佈廣泛且交通便利，為尋求糖尿病藥物的患者提供了便利的購買點。這種可近性確保患者可以在需要時及時補充處方並獲得必需的速效胰島素，從而促進更好地堅持治療方案和整體糖尿病管理。此外，藥局和零售藥局提供多種速效胰島素產品，為患者提供多種選擇，根據他們的特定需求和偏好進行選擇。這些地點的藥劑師在病患教育方面也發揮著至關重要的作用，幫助個人了解正確的胰島素給藥、潛在的副作用以及堅持用藥的重要性。此外，藥局和零售藥局經常參加健康保險計劃，這進一步方便患者獲得速效胰島素，從而可能減輕與糖尿病管理相關的財務負擔。

按地區分類：

北美洲

美國

加拿大

亞太

中國

日本

印度

韓國

澳洲

印尼

其他

歐洲

德國

法國

英國

義大利

西班牙

俄羅斯

其他

拉丁美洲

巴西

墨西哥

其他

中東和非洲

北美表現出明顯的主導地位，佔據最大的速效胰島素市場佔有率

該報告還對所有主要區域市場進行了全面分析，包括北美（美國和加拿大）、亞太地區（中國、日本、印度、韓國、澳洲、印尼等）、歐洲（德國） 、法國、英國、義大利、西班牙、俄羅斯等）、拉丁美洲（巴西、墨西哥等）以及中東和非洲。報告稱，北美佔據最大的市場佔有率。

北美地區的糖尿病盛行率很高，多年來美國和加拿大的糖尿病病例數急劇增加。該地區擁有完善的醫療基礎設施，強調糖尿病的管理和治療。先進醫療技術、胰島素輸送設備和連續血糖監測系統的使用改善了患者護理，並促進了速效胰島素療法的廣泛採用。此外，北美處於製藥業研發的前沿，導致創新且有效的速效胰島素製劑的推出。這種對進步的持續關注確保了該地區仍然是塑造糖尿病治療未來的關鍵參與者。此外，北美健全的醫療保健政策和保險覆蓋範圍使大部分人口更容易獲得糖尿病藥物，包括速效胰島素。這種便利性對該地區的主導市場佔有率做出了重大貢獻。

競爭格局：

製藥公司正大力投資研發，以發現和開發創新的速效胰島素製劑。他們的目標是改善這些胰島素的藥物動力學、起效時間和持續時間，以便更好地滿足患者的需求。此外，該公司正在探索新的胰島素輸送系統，例如超速效胰島素、口服胰島素製劑和吸入性胰島素，以提高便利性和患者依從性。此外，公司正在尋求各國衛生當局的監管批准，以擴大其速效胰島素產品的市場範圍。此外，領先企業正致力於擴大其在糖尿病患病率高的新興經濟體的業務。透過增加這些地區獲得速效胰島素的機會，他們可以挖掘未開發的市場潛力並改善全球糖尿病管理。此外，製藥公司積極參與患者教育和支持計劃，以提高人們對糖尿病管理和胰島素治療重要性的認知。

該報告對市場競爭格局進行了全面分析。也提供了所有主要公司的詳細資料。市場上的一些主要參與者包括：

阿多西亞

百康有限公司

禮來公司

甘李藥業有限公司

格羅法姆

曼肯德公司

默克公司

諾和諾德公司，

賽諾菲公司

沃克哈特有限公司

最近的發展：

2022 年 11 月，Biocon Limited 完成對 Viatris 全球生物相似藥業務的收購。此次收購為 Biocon Biologics 提供了先進市場和幾個新興市場的直接商業能力和支援基礎設施，拉近了與患者、客戶和付款人的距離。

2022 年 7 月，默克宣布與 Orion 合作開發和商業化 ODM-208，這是一種在研類固醇合成抑制劑，用於治療轉移性去勢抗性前列腺癌。

2022 年 5 月，MannKind Corporation 宣布同意從 Zealand Pharma 收購 V-Go (R) 胰島素輸送設備。收購 V-Go 使 MannKind 能夠擴大其產品組合，並加強其提供創新用餐糖尿病解決方案的承諾。

本報告回答的關鍵問題：

  • 迄今為止，全球速效胰島素市場表現如何，未來幾年將如何表現？
  • 全球速效胰島素市場的促進因素、限制因素和機會是什麼？
  • 每個促進因素、限制因素和機會對全球速效胰島素市場有何影響？
  • 主要區域市場有哪些？
  • 哪些國家代表了最具吸引力的速效胰島素市場？
  • 基於產品的市場區隔是什麼？
  • 速效胰島素市場上最具吸引力的產品是什麼？
  • 根據指示，市場的細分是什麼？
  • 速效胰島素市場中最具吸引力的適應症是什麼？
  • 基於配銷通路的市場區隔是什麼？
  • 速效胰島素市場中哪個配銷通路最具吸引力？
  • 全球速效胰島素市場的競爭結構如何？
  • 全球速效胰島素市場的主要參與者/公司有哪些？

本報告回答的關鍵問題：

  • 迄今為止，全球速效胰島素市場表現如何，未來幾年將如何表現？
  • 全球速效胰島素市場的促進因素、限制因素和機會是什麼？
  • 每個促進因素、限制因素和機會對全球速效胰島素市場有何影響？
  • 主要區域市場有哪些？
  • 哪些國家代表了最具吸引力的速效胰島素市場？
  • 基於產品的市場區隔是什麼？
  • 速效胰島素市場上最具吸引力的產品是什麼？
  • 根據指示，市場的細分是什麼？
  • 速效胰島素市場中最具吸引力的適應症是什麼？
  • 基於配銷通路的市場區隔是什麼？
  • 速效胰島素市場中哪個配銷通路最具吸引力？
  • 全球速效胰島素市場的競爭結構如何？
  • 全球速效胰島素市場的主要參與者/公司有哪些？

目錄

第 1 章：前言

第 2 章：範圍與方法

  • 研究目的
  • 利害關係人
  • 資料來源
    • 主要資源
    • 二手資料
  • 市場預測
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第 3 章：執行摘要

第 4 章：簡介

  • 概述
  • 主要行業趨勢

第 5 章：全球速效胰島素市場

  • 市場概況
  • 市場業績
  • COVID-19 的影響
  • 市場預測

第 6 章：按產品分類的市場區隔

  • 賴脯胰島素
    • 市場走向
    • 市場預測
  • 門冬胰島素
    • 市場走向
    • 市場預測
  • 谷賴胰島素
    • 市場走向
    • 市場預測

第 7 章：按跡象分類的市場

  • 1 型糖尿病
    • 市場走向
    • 市場預測
  • 2型糖尿病
    • 市場走向
    • 市場預測

第 8 章：按配銷通路分類的市場區隔

  • 醫院藥房
    • 市場走向
    • 市場預測
  • 藥局和零售藥局
    • 市場走向
    • 市場預測
  • 網路商店
    • 市場走向
    • 市場預測

第 9 章：按地區分類的市場區隔

  • 北美洲
    • 美國
      • 市場走向
      • 市場預測
    • 加拿大
      • 市場走向
      • 市場預測
  • 亞太
    • 中國
      • 市場走向
      • 市場預測
    • 日本
      • 市場走向
      • 市場預測
    • 印度
      • 市場走向
      • 市場預測
    • 韓國
      • 市場走向
      • 市場預測
    • 澳洲
      • 市場走向
      • 市場預測
    • 印尼
      • 市場走向
      • 市場預測
    • 其他
      • 市場走向
      • 市場預測
  • 歐洲
    • 德國
      • 市場走向
      • 市場預測
    • 法國
      • 市場走向
      • 市場預測
    • 英國
      • 市場走向
      • 市場預測
    • 義大利
      • 市場走向
      • 市場預測
    • 西班牙
      • 市場走向
      • 市場預測
    • 俄羅斯
      • 市場走向
      • 市場預測
    • 其他
      • 市場走向
      • 市場預測
  • 拉丁美洲
    • 巴西
      • 市場走向
      • 市場預測
    • 墨西哥
      • 市場走向
      • 市場預測
    • 其他
      • 市場走向
      • 市場預測
  • 中東和非洲
    • 市場走向
    • 按國家/地區分類的市場細分
    • 市場預測

第 10 章：SWOT 分析

  • 概述
  • 優勢
  • 弱點
  • 機會
  • 威脅

第 11 章：價值鏈分析

第 12 章：波特五力分析

  • 概述
  • 買家的議價能力
  • 供應商的議價能力
  • 競爭程度
  • 新進入者的威脅
  • 替代品的威脅

第 13 章：價格分析

第14章：競爭格局

  • 市場結構
  • 關鍵參與者
  • 關鍵參與者簡介
    • Adocia
    • Biocon Limited
    • Eli Lilly and Company
    • Gan & Lee Pharmaceuticals Co. Ltd.
    • Geropharm
    • MannKind Corporation
    • Merck & Co. Inc.
    • Novo Nordisk A/S
    • Sanofi SA
    • Wockhardt Ltd.
Product Code: SR112023A4783

Abstract

The global rapid acting insulin market size reached US$ 7.4 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 9.7 Billion by 2028, exhibiting a growth rate (CAGR) of 4.61% during 2022-2028. The increasing risks of severity and mortality among patients, the growing focus on personalized medicine among the masses, and the increasing investments in research and development (R&D) activities are some of the major factors propelling the market.

A rapid-acting insulin is a type of insulin used in the treatment of diabetes, specifically for managing post-meal blood sugar spikes. It is designed to mimic the body's natural insulin response after eating, with an onset of action within 15 minutes of injection. This swift action helps to control blood sugar levels effectively, as it works to regulate the body's metabolism of glucose. Rapid-acting insulin peaks in its effect around one to two hours after administration, enabling it to efficiently lower high blood sugar levels during this critical period. It allows individuals with diabetes to time their injections in correlation with meal consumption, providing a more personalized treatment approach. It enhances diabetes management, providing patients with a better quality of life and reducing the risk of complications associated with uncontrolled blood sugar levels.

A rapid-acting insulin is a type of insulin used in the treatment of diabetes, specifically for managing post-meal blood sugar spikes. It is designed to mimic the body's natural insulin response after eating, with an onset of action within 15 minutes of injection. This swift action helps to control blood sugar levels effectively, as it works to regulate the body's metabolism of glucose. Rapid-acting insulin peaks in its effect around one to two hours after administration, enabling it to efficiently lower high blood sugar levels during this critical period. It allows individuals with diabetes to time their injections in correlation with meal consumption, providing a more personalized treatment approach. It enhances diabetes management, providing patients with a better quality of life and reducing the risk of complications associated with uncontrolled blood sugar levels.

Rapid Acting Insulin Market Trends/Drivers:

The Increasing Prevalence of Diabetes Among the Masses

The incidences of diabetes have been escalating at an alarming rate worldwide. Sedentary lifestyles, unhealthy dietary habits, and obesity are some of the key factors contributing to the rising incidence of diabetes. As more individuals are diagnosed with diabetes, the demand for effective and rapid-acting insulin continues to grow. Rapid-acting insulin plays a crucial role in managing post-meal blood sugar spikes, providing patients with a faster and more efficient way to control their glucose levels. Healthcare providers increasingly prescribe rapid-acting insulin to address the immediate insulin needs after meals, reducing the risk of hyperglycemia and associated complications. As the diabetic population expands, pharmaceutical companies are investing more in research and development to improve rapid-acting insulin formulations, enhancing their efficacy and convenience for patients.

Continual Technological Advancements

Innovations in medical technology have revolutionized insulin delivery systems, making them more user-friendly and accurate. Insulin pens, insulin pumps, and continuous glucose monitoring (CGM) devices have become increasingly popular among diabetes patients, facilitating easier administration and precise dosing of insulin. Rapid-acting insulin formulations are designed to work optimally with these modern delivery systems, further fueling their demand. Insulin pens offer discreet and convenient insulin delivery, while insulin pumps provide a continuous and personalized insulin infusion based on individual needs. These technological innovations have improved glycemic control, reduced the risk of hypoglycemic episodes, and enhanced patient's overall quality of life. As a result, the compatibility of rapid-acting insulin with these advanced devices has become a significant driving force behind the market's growth.

Increasing Awareness and Healthcare Infrastructure

Growing awareness about diabetes and its management, coupled with the expansion of healthcare infrastructure, has significantly contributed to the demand for rapid-acting insulin. Diabetes awareness campaigns, educational initiatives, and screening programs have led to early diagnosis and timely intervention for patients, increasing the number of individuals seeking appropriate treatment. Physicians and healthcare professionals are increasingly prescribing rapid-acting insulin to help patients achieve better post-prandial glucose control, preventing hyperglycemic episodes and long-term complications. Moreover, governments and healthcare organizations are investing in diabetes management programs, improving access to essential medications, including rapid-acting insulin. The combination of heightened awareness, better healthcare facilities, and increased affordability of diabetes treatment has created a favorable environment for the rapid-acting insulin market's expansion.

Rapid Acting Insulin Industry Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global rapid acting insulin market report, along with forecasts at the global, regional and country levels from 2023-2028. Our report has categorized the market based on product, indication and distribution channel.

Breakup by Product:

Lispro Insulin

Aspart Insulin

Glulisine Insulin

Lispro insulin dominates the market

The report has provided a detailed breakup and analysis of the market based on the product. This includes lispro insulin, aspart insulin and glulisine insulin. According to the report, lispro insulin represented the largest segment.

Lispro insulin's popularity can be attributed to its fast onset of action, typically within a few minutes after administration, which helps control post-meal blood sugar spikes more effectively. This rapid action allows individuals with diabetes to time their insulin injections closer to meal consumption, providing greater flexibility and convenience in managing their blood glucose levels. Moreover, Lispro insulin is compatible with various insulin delivery devices, such as insulin pens and insulin pumps, further enhancing its ease of use and patient compliance. Apart from this, numerous physicians and healthcare providers frequently prescribe Lispro insulin due to its proven efficacy and safety profile. It has demonstrated its effectiveness in managing both type 1 and type 2 diabetes, making it a versatile option for a wide range of patients.

Breakup by Indication:

Type 1 Diabetes

Type 2 Diabetes

Type 2 diabetes hold the largest share in the market

A detailed breakup and analysis of the market based on the indication has also been provided in the report. This includes type 1 diabetes and type 2 diabetes. According to the report, type 2 diabetes accounted for the largest market share.

Type 2 diabetes is a chronic metabolic disorder characterized by insulin resistance and impaired glucose regulation, leading to elevated blood sugar levels. Rapid-acting insulin plays a crucial role in the management of type 2 diabetes, particularly in addressing post-meal hyperglycemia. After a meal, individuals often experience a rapid increase in blood sugar levels, which can contribute to various health complications if left uncontrolled. As awareness about diabetes and its management continues to rise, coupled with the efforts to improve access to healthcare and diabetes care, the demand for rapid-acting insulin is expected to remain significant, solidifying its prominent position in the market. The increasing prevalence of type 2 diabetes, driven by factors like sedentary lifestyles, obesity, and an aging population, has resulted in a growing patient pool seeking diabetes management solutions.

Breakup by Distribution Channel:

Hospital Pharmacies

Drug Stores and Retail Pharmacies

Online Stores

Drug stores and retail pharmacies hold the largest share in the market

A detailed breakup and analysis of the market based on the distribution channel has also been provided in the report. This includes hospital pharmacies, drug stores and retail pharmacies and online stores. According to the report, drug stores and retail pharmacies accounted for the largest market share.

Drug stores and retail pharmacies are widespread and easily accessible, making them convenient points of purchase for patients seeking their diabetes medications. This accessibility ensures that patients can promptly refill their prescriptions and access essential rapid-acting insulin whenever needed, promoting better adherence to treatment regimens and overall diabetes management. Moreover, drug stores and retail pharmacies offer a diverse range of rapid-acting insulin products, providing patients with multiple options to choose from based on their specific needs and preferences. Pharmacists at these locations also play a vital role in patient education, helping individuals understand proper insulin administration, potential side effects, and the importance of medication adherence. Additionally, drug stores and retail pharmacies often participate in health insurance plans, which further facilitates access to rapid-acting insulin for patients, potentially reducing the financial burden associated with diabetes management.

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

North America exhibits a clear dominance, accounting for the largest rapid acting insulin market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada), Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others), Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others), Latin America (Brazil, Mexico, and others), and the Middle East and Africa. According to the report, North America accounted for the largest market share.

North America boasts a high prevalence of diabetes, with both the United States and Canada experiencing an alarming increase in diabetes cases over the years. The region has a well-established healthcare infrastructure that emphasizes diabetes management and treatment. Access to advanced medical technologies, insulin delivery devices, and continuous glucose monitoring systems has enhanced patient care and contributed to the widespread adoption of rapid-acting insulin therapies. Moreover, North America is at the forefront of research and development in the pharmaceutical industry, leading to the introduction of innovative and effective rapid-acting insulin formulations. This continuous focus on advancements ensures that the region remains a key player in shaping the future of diabetes treatment. Furthermore, robust healthcare policies and insurance coverage in North America facilitate easier access to diabetes medications, including rapid-acting insulin, for a large portion of the population. This accessibility has significantly contributed to the region's dominant market share.

Competitive Landscape:

Pharmaceutical companies are investing heavily in R&D to discover and develop innovative rapid-acting insulin formulations. They aim to improve the pharmacokinetics, onset of action, and duration of these insulins to better meet the needs of patients. Additionally, companies are exploring new insulin delivery systems, such as ultra-rapid-acting insulins, oral insulin formulations, and inhalable insulin, to enhance convenience and patient compliance. Moreover, companies are pursuing regulatory approvals from health authorities in various countries to expand the market reach of their rapid-acting insulin products. Furthermore, leading players are focusing on expanding their presence in emerging economies with a high prevalence of diabetes. By increasing access to rapid-acting insulin in these regions, they can tap into untapped market potential and improve diabetes management globally. Additionally, pharmaceutical companies are actively involved in patient education and support programs to raise awareness about diabetes management and the importance of insulin therapy.

The report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

Adocia

Biocon Limited

Eli Lilly and Company

Gan & Lee Pharmaceuticals Co. Ltd.

Geropharm

MannKind Corporation

Merck & Co. Inc.

Novo Nordisk A/S,

Sanofi S.A.

Wockhardt Ltd.

Recent Developments:

In November 2022, Biocon Limited Completes Acquisition of Viatris' Global Biosimilars Business. The acquisition provides Biocon Biologics with direct commercial capabilities and supporting infrastructure in the advanced markets and several emerging markets, bringing it closer to patients, customers, and payors.

In July 2022, Merck & Co. Inc. announces its collaboration with Orion, Global Collaboration for the Development and Commercialization of ODM-208, an investigational steroid synthesis inhibitor for the treatment of metastatic castration-resistant prostate cancer.

In May 2022, MannKind Corporation Announces Agreement to Acquire V-Go® Insulin Delivery Device from Zealand Pharma. The acquisition of V-Go allows MannKind to expand its portfolio and strengthen its commitment to providing innovative mealtime diabetes solutions.

Key Questions Answered in This Report:

  • How has the global rapid acting insulin market performed so far, and how will it perform in the coming years?
  • What are the drivers, restraints, and opportunities in the global rapid acting insulin market?
  • What is the impact of each driver, restraint, and opportunity on the global rapid acting insulin market?
  • What are the key regional markets?
  • Which countries represent the most attractive rapid acting insulin market?
  • What is the breakup of the market based on the product?
  • Which is the most attractive product in the rapid acting insulin market?
  • What is the breakup of the market based on the indication?
  • Which is the most attractive indication in the rapid acting insulin market?
  • What is the breakup of the market based on the distribution channel?
  • Which is the most attractive distribution channel in the rapid acting insulin market?
  • What is the competitive structure of the global rapid acting insulin market?
  • Who are the key players/companies in the global rapid acting insulin market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Rapid Acting Insulin Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Product

  • 6.1 Lispro Insulin
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Aspart Insulin
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Glulisine Insulin
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast

7 Market Breakup by Indication

  • 7.1 Type 1 Diabetes
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Type 2 Diabetes
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8 Market Breakup by Distribution Channel

  • 8.1 Hospital Pharmacies
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Drug Stores and Retail Pharmacies
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Online Stores
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Adocia
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
    • 14.3.2 Biocon Limited
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 Eli Lilly and Company
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Gan & Lee Pharmaceuticals Co. Ltd.
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
    • 14.3.5 Geropharm
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
    • 14.3.6 MannKind Corporation
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis
    • 14.3.7 Merck & Co. Inc.
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
      • 14.3.7.4 SWOT Analysis
    • 14.3.8 Novo Nordisk A/S
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
      • 14.3.8.4 SWOT Analysis
    • 14.3.9 Sanofi S.A.
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
      • 14.3.9.4 SWOT Analysis
    • 14.3.10 Wockhardt Ltd.
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials

List of Figures

  • Figure 1: Global: Rapid Acting Insulin Market: Major Drivers and Challenges
  • Figure 2: Global: Rapid Acting Insulin Market: Sales Value (in Billion US$), 2017-2022
  • Figure 3: Global: Rapid Acting Insulin Market Forecast: Sales Value (in Billion US$), 2023-2028
  • Figure 4: Global: Rapid Acting Insulin Market: Breakup by Product (in %), 2022
  • Figure 5: Global: Rapid Acting Insulin Market: Breakup by Indication (in %), 2022
  • Figure 6: Global: Rapid Acting Insulin Market: Breakup by Distribution Channel (in %), 2022
  • Figure 7: Global: Rapid Acting Insulin Market: Breakup by Region (in %), 2022
  • Figure 8: Global: Rapid Acting Insulin (Lispro Insulin) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 9: Global: Rapid Acting Insulin (Lispro Insulin) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 10: Global: Rapid Acting Insulin (Aspart Insulin) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 11: Global: Rapid Acting Insulin (Aspart Insulin) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 12: Global: Rapid Acting Insulin (Glulisine Insulin) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 13: Global: Rapid Acting Insulin (Glulisine Insulin) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 14: Global: Rapid Acting Insulin (Type 1 Diabetes) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 15: Global: Rapid Acting Insulin (Type 1 Diabetes) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 16: Global: Rapid Acting Insulin (Type 2 Diabetes) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 17: Global: Rapid Acting Insulin (Type 2 Diabetes) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 18: Global: Rapid Acting Insulin (Hospital Pharmacies) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 19: Global: Rapid Acting Insulin (Hospital Pharmacies) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 20: Global: Rapid Acting Insulin (Drug Stores and Retail Pharmacies) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 21: Global: Rapid Acting Insulin (Drug Stores and Retail Pharmacies) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 22: Global: Rapid Acting Insulin (Online Stores) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 23: Global: Rapid Acting Insulin (Online Stores) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 24: North America: Rapid Acting Insulin Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 25: North America: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 26: United States: Rapid Acting Insulin Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 27: United States: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 28: Canada: Rapid Acting Insulin Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 29: Canada: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 30: Asia-Pacific: Rapid Acting Insulin Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 31: Asia-Pacific: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 32: China: Rapid Acting Insulin Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 33: China: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 34: Japan: Rapid Acting Insulin Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 35: Japan: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 36: India: Rapid Acting Insulin Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 37: India: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 38: South Korea: Rapid Acting Insulin Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 39: South Korea: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 40: Australia: Rapid Acting Insulin Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 41: Australia: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 42: Indonesia: Rapid Acting Insulin Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 43: Indonesia: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 44: Others: Rapid Acting Insulin Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 45: Others: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 46: Europe: Rapid Acting Insulin Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 47: Europe: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 48: Germany: Rapid Acting Insulin Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 49: Germany: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 50: France: Rapid Acting Insulin Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 51: France: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 52: United Kingdom: Rapid Acting Insulin Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 53: United Kingdom: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 54: Italy: Rapid Acting Insulin Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 55: Italy: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 56: Spain: Rapid Acting Insulin Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 57: Spain: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 58: Russia: Rapid Acting Insulin Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 59: Russia: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 60: Others: Rapid Acting Insulin Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 61: Others: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 62: Latin America: Rapid Acting Insulin Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 63: Latin America: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 64: Brazil: Rapid Acting Insulin Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 65: Brazil: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 66: Mexico: Rapid Acting Insulin Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 67: Mexico: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 68: Others: Rapid Acting Insulin Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 69: Others: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 70: Middle East and Africa: Rapid Acting Insulin Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 71: Middle East and Africa: Rapid Acting Insulin Market: Breakup by Country (in %), 2022
  • Figure 72: Middle East and Africa: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 73: Global: Rapid Acting Insulin Industry: SWOT Analysis
  • Figure 74: Global: Rapid Acting Insulin Industry: Value Chain Analysis
  • Figure 75: Global: Rapid Acting Insulin Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Rapid Acting Insulin Market: Key Industry Highlights, 2022 and 2028
  • Table 2: Global: Rapid Acting Insulin Market Forecast: Breakup by Product (in Million US$), 2023-2028
  • Table 3: Global: Rapid Acting Insulin Market Forecast: Breakup by Indication (in Million US$), 2023-2028
  • Table 4: Global: Rapid Acting Insulin Market Forecast: Breakup by Distribution Channel (in Million US$), 2023-2028
  • Table 5: Global: Rapid Acting Insulin Market Forecast: Breakup by Region (in Million US$), 2023-2028
  • Table 6: Global: Rapid Acting Insulin Market: Competitive Structure
  • Table 7: Global: Rapid Acting Insulin Market: Key Players